

Cambridge University Press

978-0-521-76431-5 - Ethics and the Business of Biomedicine

Edited by Denis G. Arnold

Index

[More information](#)*Index*

- Abramson, John 250
 academic detailing 118–121
 accountability
 justice and 39, 55
 market-friendly systems 54, 55
 organizational ethics 238
 Actimmune 8
 administration costs 42
 adoption 158
 advance directives 232
 Advanced Cell Technologies 152
 advanced market commitments 75–76
 advertising. *See* DTC advertising; marketing
 Affymetrix 151
 agency 104, 113
 aging population 42
 AIDS 5, 52, 103, 121, 170, 187–189, 193–194
 Allegheny Health Education and Research
 Foundation 203
 American Association of Retired Persons 142
 American College of Surgeons 225
 American Council on Graduate Medical
 Education 207
 American Enterprise Institute 23
 American Medical Association 22, 113, 114, 117,
 152, 206, 225
 American Society of Bioethics and
 Humanities 156
 Amgen 10
 Angell, Marcia 21, 63, 72–73, 77, 119, 120, 250
 anti-free-riding principle 69
 anti-retroviral therapies 52
 antidepressants 11
 Aquinas, Thomas 185
 Arizona State University 151
 Arnold, Denis 10, 131
 Arrow, Kenneth 255
 Arthritis Foundation 159
 Association of the British Pharmaceutical
 Industry (ABPI) 104, 106, 114
 Astra Zeneca 151
 atomism 229–230
 Australia 171
 autonomy 104–109, 113, 148
 Avastin 176
 Aventis 4
 avian flu 173
 Avorn, Jerry 250
 AZT 121
 Bayer 9, 136
 BBC 205
 Beauchamp, Tom 7, 83–97
 Beecher, Henry 199
 Belgium 27
 Belsito, Marybeth 160
 Bernays, Edward 159
 bias
 disclosure worsening bias 162–165
 DTP marketing and 104–109
 medical journals 111
 self-serving bias 164
 bioethicists, power 155
 bioethics
 industry funding. *See* industry-funded
 bioethics
 models. *See* healthcare models
 biomedical model
 alternative paradigm 236–244
 characteristics 222–227
 complicity of bioethics 231–234
 cost crisis 230–231
 critics 234–236
 depersonalizing medicine 227–229
 ethical norms and economic structures 225–226
 fragmentation of care 229–230
 grounding in sciences 223
 health as absence of disease 224–225
 orthodoxy 231–234
 paternalism 228
 physician-centered 226, 232
 problems 227–231

Cambridge University Press

978-0-521-76431-5 - Ethics and the Business of Biomedicine

Edited by Denis G. Arnold

Index

[More information](#)

284

Index

- biomedical model (cont.)
 - reductionism 227
 - role of institutions 226–227
 - shift from 14, 220, 234–236
- biopsychological model 222, 234–235, 239
- biotechnology 155
- Biotechnology Trade Organization 151
- Bismarck, Otto von 27
- Bloch, Gregg 255
- Blue Cross Blue Shield 151
- Boniva 140
- Boorse, Christopher 224
- Bowen, Angela 154
- Brenkert, George 126
- bribery 115, 163–164
- Bush, George W. 24, 29, 36
- business
 - corrupting influence 15, 249–255
 - medicine as 22, 199–200, 204–205, 237
 - organizational ethics and 226–227
- Callahan, Daniel 3, 20–33
- Canada
 - drug prices 70, 190
 - healthcare expenditure 2, 32
 - healthcare system 3, 20, 26–27, 30–31, 39
 - parallel trade 71
 - private health insurance and 28–29
 - private healthcare 174
 - unit costs 42–43
- cancer 103, 176, 242
- Carnegie Foundation 14, 198, 215, 249
- Carnegie Mellon University 162–163
- cartoon 252
- Cato Institute 24
- Celebrex 9, 139, 159
- Center for Global Development (CGD) 75, 76
- Cephalon 8
- Cerezyme 176
- China 27, 256
- Cialdini, Robert 157
- Claritin 10, 136, 138–139
- Cleveland Clinic 163–164
- clinical trials
 - background justice 95–97
 - comparative trials *iii*
 - compromised consent 94–95
 - constraining situations 89
 - developing countries and 6–7
 - disclosure 10–12
 - economically disadvantaged 83–84
 - exclusion option 87–88
 - exploitation 89–93
 - vulnerability 84–87
 - ethics committees and 153
 - payment as inducement 84, 88–93
 - risk 90–93, 94
 - types of influence 88–89
 - undue influence 89–93, 94
 - undue profits 90–93, 94
 - voluntariness 88–89
- Clinton, Bill 25, 36, 44–45, 202
- cloning 155
- co-payments 28, 29, 30
- coercion 89, 90, 158
- commodification 157–158
- comparative drug trials *iii*
- competition
 - broken promises 35–36
 - competitive plans and access to drugs 49–50
 - control of cost increases 44–45
 - healthcare strategies 28, 29, 30
 - lowering unit prices 41–44
 - managed competition 52, 57
 - monopolies 43–44, 50
 - monopsonies 43, 44, 45, 50
 - non-innovative drugs 66–67
- compulsory licensing 5, 183
- conflicts of interest
 - See also* industry-funded bioethics
 - conflicts of interest committees 214
 - corruption of US healthcare 249–255
 - disclosure remedy 150–151, 165–166
 - non-disclosure problem 155–157
 - pervasiveness 254
 - rules 253
- consent
 - clinical trials 88–93, 94–95
 - compromised consent 94–95
 - informed consent 232
 - payment and 88–93
 - undue influence 89–93
- consultants 152
- consumer-driven health plans (CDHPs) 45–49, 56, 57
- consumers. *See* DTC advertising
- continuing medical education 117
- Contract Research Organizations (CROs) 153
- copyright 64–65
- corporatization of medicine 201–202
- corruption
 - business corrupting US healthcare 15, 249–255
 - industry-funded bioethics 161
- costs
 - administrative complexity 42
 - annual healthcare expenditure 1–2
 - broken promises 36, 41–52

Cambridge University Press

978-0-521-76431-5 - Ethics and the Business of Biomedicine

Edited by Denis G. Arnold

Index

[More information](#)*Index*

285

- CDHPs, effect 45–49
- competition and access to drugs 49–50
- control of increases and competition
 - 44–45
- drugs 169
- DTC advertising and 134, 138–139
- malpractice costs 42
- marginal social costs 82
- unit prices and competition 41–44
- US cost crisis 230–231
- cox-2 inhibitors 108, 139, 159
- Czech Republic 27

- Daniels, Norman 3, 35–57, 180
- Davis, Phil 205
- De George, Richard 12–13, 169–171, 195
- deception, DTP marketing 104–109
- DeCode Genetics 152
- deductibles 28, 29, 46, 47
- democracy 23–24, 56
- demographics 42
- Denmark 27
- depersonalization of medicine 227–229
- detailing
 - academic detailing 118–121
 - bribery 115
 - deception, bias and autonomy 104–109
 - educative value 106–107
 - gifts 113–116, 163–164
 - impact 8, 204
 - innovation v. regulation 118–121
 - manipulation 112–113
 - meaning 103
 - practices 7, 103
 - prescribing behavior and 116
 - regulation 117–118
 - rep techniques 8
 - threat to patients 107–109, 111–112, 116
 - trips 163
 - vulnerability of physicians 109–112
- developing countries
 - access to drugs 187–189, 193–195
 - clinical trials in 6–7, 83–84
 - drug market 67
 - drug patents and 4–6, 69–70
 - health funding 6, 36, 50
 - immunization programs 53
 - orphan drugs 74, 194–195
 - privatizations 51, 57
 - user fees 51–52, 57
 - vulnerability 84–87
- diabetes 217
- diarrhoeal diseases 74
- Dickens, Charles 205
- dignity 140

- disclosure
 - non-disclosure problem 155–157
 - remedy against conflicts of interests 150–151, 165–166
 - worsening bias 162–165
- disease, concept 224–225
- doctors. *See* physicians
- Doha Declaration on TRIPS and Health 6, 72, 74, 77
- Dow 152
- drug industry
 - access obligations 184
 - clinical trials. *See* clinical trials
 - contribution 12–13, 169
 - corrupting influence 251–253
 - criticisms 169–171, 189–195
 - DTP marketing. *See* detailing
 - funding bioethics. *See* industry-funded bioethics
 - influence 3–13, 83–84
 - international shortcomings 193–195
 - lobbying 190
 - marketing. *See* marketing
 - monopoly powers 43–44, 50
 - obligations 182–189
 - patents. *See* drug patents
 - production obligations 182–183
 - profitability 3–4, 103, 155, 191–195
 - regulation v. innovation 12, 118–121
 - rescue obligations 184–189
 - right to health and 171–177
 - social responsibility 188, 193
 - ties with medical journals 11, 15, 111, 152, 156, 251
 - withholding data 111
- drug patents
 - See also* research and development
 - compulsory licensing 5, 183
 - developing countries and 4–6, 67
 - factual context 65–67
 - free-riding and 67–71
 - income inequalities and 69–70
 - innovation 65
 - issues 66–67
 - marketing and 67
 - misplaced criticism 189
 - non-innovative drugs 65, 66–67, 69–71, 119
 - paying for innovation 73–76
 - reform 71–73
- drugs
 - 10/90 gap 66
 - comparative trials 111
 - marginal social costs 82
 - Medicare and access to 49–50
 - off-label uses 7, 251
 - orphan drugs 74, 181–182, 183, 194–195

Cambridge University Press

978-0-521-76431-5 - Ethics and the Business of Biomedicine

Edited by Denis G. Arnold

Index

[More information](#)

286

drugs (cont.)
 parallel trade 71
 patents. *See* drug patents
 prescription drugs, nature 141, 179–181
 pricing
 British system 73
 criticism 190–191
 reference pricing 81
 tiered pricing 190–191
 US control 178–179
 public goods 67–71
 safety 10–11, 141
 US expenditure 65, 70–71
 very expensive drugs 176–177
 Drugs for Neglected Diseases Initiative 195
 DTC advertising
 branded ads 135
 categories 133, 135–136
 debate 131, 133–136
 educative function 133–134, 135, 142–143
 ethical legitimacy 136–144
 European ban 31
 healthcare costs and 134, 138–139
 help-seeking ads 133, 144
 information lacuna 179–181
 manipulative advertising 143
 nature of prescription drugs 141, 179–181
 non-branded 136, 144
 over-medication and 134, 135, 138–139
 patient–physician relationships 134–135, 143
 PhRMA guidelines 136–137, 145–146
 product claim ads 133, 137–143
 public safety and 141
 reminder advertising 133, 136–137
 rise 131–133
 statements of adverse effects 132, 133
 television 131, 132, 180
 United States 9–10, 131–146, 179–181
 DTP marketing. *See* detailing
 Dupont 152
 Eddy, David 238
 education
 continuing medical education 117
 US medical education 14–15, 207–209, 223–227
 Eflornithine 4
 Eli Lilly 8, 11, 160
 Elliott, Carl 11–12, 107, 150–166
 Enbrel 10, 240
 end of life care 233–234
 Engel, George 222, 227, 234–235, 236, 237, 239, 240–241
 Erbitux 176
 errors 238
 ESSEC Business School, Paris 151

Index

Ethiopia 4
 European Federation of Pharmaceutical Industries and Associations (EFPIA) 194
 European Union 131
 Families USA 120
 fee splitting 225
 fiduciary ethos 105, 115, 226, 241
 Field, Sally 140
 Finland 106, 107
 Flexner II 15, 255–257
 Flexner Report 14–15, 199, 215, 249, 250
 Flexnerian model 200, 223–234, 243
 Ford 136
 fragmentation of care 229–230
 France 2, 27, 70, 190
 free-riding 67–71
 Friedman, Milton 23
 Fuchs, Victor 25
 Garber, Alan 181
 Gaucher disease 176
 Genentech 176
 Germany 24, 27, 44, 70, 81, 190
 gifts, drug companies to physicians 113–116, 163–164
 GlaxoSmithKline 5, 9, 11, 136, 152
 Gorman, Michael 65
 Gustafson, James 231
 Harvard Medical School 110
 Hastings Center 151
 Hauerwas, Stanley 231
 Hayek, Friedrich von 23
 health
 definition 224–225
 holistic health concepts 239–240
 patients and communities 240–242
 public health 31, 250
 right to 12–13, 170, 171–177
 social context 240–242
 health reimbursement accounts (HRAs) 45, 47
 health savings accounts (HSAs) 29, 36, 44, 46
 healthcare
 costs. *See* costs
 market fallacy 33
 markets 20
 meaning 37–38
 medicine and 240
 models. *See* healthcare models
 right to 12–13, 170, 171–177
 social good 174
 strategies. *See* healthcare strategies

Cambridge University Press

978-0-521-76431-5 - Ethics and the Business of Biomedicine

Edited by Denis G. Arnold

Index

[More information](#)

Index

287

- healthcare models
 - biomedical model 222–227
 - problems 227–231
 - biopsychological model 222, 230, 234–235
 - business rhetoric 22, 199–200, 204–205, 237
 - changing delivery conditions 200–204
 - changing rhetoric 198–200
 - complicity 231–234
 - corporatization of medicine 201–202
 - function of bioethics 233
 - medical professionalism and 13–15
 - objectives 13, 199–200
 - interaction 203
 - organization ethics 212–215, 226–227, 236–244
 - organizational changes 198
 - orthodoxy 231–234
 - patient care and research 205–215
 - shift 14, 220, 234–236
 - stakeholders 208, 209–212
 - systems-based model 14, 206–209, 221, 234–236
 - value-based stakeholder approach 209–212
- healthcare strategies
 - choice and democracy 23–24
 - commercial model 21–22
 - competition. *See* competition
 - deductibles and co-payments 28, 29, 30
 - efficiency 23
 - ethical issues 20
 - Europe and Canada 20, 26–27, 30–31, 32, 39
 - European debate 23
 - evaluation of market practices 28–30
 - evaluation of practices 28–30
 - for-profit v. non-profit 29
 - government-dominated 20–21
 - government-run 24
 - ideologies 23–24, 25
 - instrumentalism 23, 25
 - intertwined values 24–25
 - justice and 1–3, 23, 24, 36–41
 - market strategies. *See* market strategies
 - models 3
 - national systems 26–27
 - physician incentives 29
 - private health insurance 28–29
 - social solidarity and 49
 - standards of judgment 26
 - United States. *See* United States
 - universal systems 20–21, 39, 40
- Helsinki Declaration 79
- Hemminki, Elina 106, 107
- Herceptin 176
- Heritage Foundation 24
- high-deductible plans 46, 47
- Hippocratic tradition 198, 205, 212, 216, 226
- holism 239–240
- Horton, Richard 251
- Hubbard, Jason 8, 103–121
- Hubbard, Tim 82
- Hugo, Victor, *Les Misérables* 185–186
- human rights
 - right to health 12–13, 171–177
 - right to life 172, 176
- Imber, Jonathan 233
- IMF 51
- immunization programs 53
- India 5, 27, 256
- individualism 240–242
- industry-funded bioethics
 - conflicts of interests 11–12, 150, 154, 161
 - consultants 152
 - corruption 161, 249–255
 - disclosure remedy 150–151, 165–166
 - disclosure worsening bias 162–165
 - effect on ethical behaviour 166
 - forms 150, 151–154
 - influence 151, 165
 - IRBs 153
 - lectures 153–154
 - medical editors 11, 15, 111, 152, 156, 251
 - non-disclosure problem 155–157
 - public relations 158–160
 - public trust and 161
 - rebound effects 157–158
 - social causes 154–155
 - unnecessary funding 166
- influence
 - coercion 89, 90, 158
 - industry-funded bioethics 151, 165
 - industry spending for 253
 - manipulation 88–89, 90, 94
 - payment and clinical research 88–93
 - persuasion 88
 - types 88–89
 - undue influence 89–93, 94
- Ingraham, Leslie 155
- innovation
 - infinite technological innovation 31–33
 - paying for 73–76
 - regulation v. innovation 12, 118–121
- Institutes of Medicine 207, 221, 222, 234, 235–236, 237, 238
- Institutional Review Boards (IRBs) 153–154, 232
- institutions
 - biomedical model 226–227
 - organizational ethics 238–239
- instrumentalism 23, 25

Cambridge University Press

978-0-521-76431-5 - Ethics and the Business of Biomedicine

Edited by Denis G. Arnold

Index

[More information](#)

288

insurance
 biomedical model 230
 private health insurance 28–29
 uninsurance 2, 52, 181
 US premiums 2
 intellectual property rights 4, 63–65
 See also drug patents; patents
 InterMune 8
 Internet 159
 Israel 27
 Italy 27, 70, 190

 Jack, William 82
 Japan 171, 192
 Johns Hopkins School of Medicine 223
 Johnson & Johnson 11, 13
 Joint Commission for Accreditation of
 Health Care Organizations (JCAHO)
 212–213, 215
 Jonas, Hans 231
 journals. *See* medical journals
 justice
 ability to pay 40
 access to drugs 49–50, 69–70, 75
 benchmarks 40–41, 55–57
 CDHPs and 48
 clinical trials and 95–97
 free-riding on research and 68–69
 healthcare markets 1–3, 23, 24, 36–41
 lobbying and 190
 market mechanism 170
 Les Misérables 185–186
 Rawls 37, 38–39

 Kaiser Family Foundation 143
 Kant, Immanuel 104, 140
 Kark, Sidney 247
 Kass, Leon 231
 Kassirer, Jerome 22, 117, 250, 254
 Key Opinion Leaders 153, 251
 Khushf, George 14, 220–244
 Kleinfeld, N. R. 217
 Kleinke, J. D. 217
 Krinsky, Sheldon 156
 Kryzewski, Mike 158

 Lanjouw, Jean Olson 63, 72, 77, 82
 lectures 153–154
 Leder, Drew 231, 233
 Levitra 9, 136
 Lexchin, Joel 71
 life, right to 172, 176
 life expectancy 169
 Light, Donald 71, 75, 76
 Lipitor 8, 9

Index

lobbying 190
 Locke, John 64, 185
 Love, James 82
 Lunesta 137, 140

 McKenny, Gerald 231
 McKinnell, Hank 133–134
 Maitland, Ian 129, 192
 malaria 4, 74
 malpractice costs 42
 manipulation 88–89, 90, 94, 112–113, 143
 marginal social costs 82
 market fallacy 33
 market strategies
 accountability 54, 55
 broken promises 35–36, 41–52
 competition. *See* competition
 developing countries and 50
 effectiveness 170
 ethical and scientific review 52–57
 evaluation of market practices 28–30
 health costs promise 36
 healthcare models 30
 market-friendly solutions 35–36
 United States 3, 35–57
 advertising control 179–181
 drug pricing 178–179
 market failures 181–182
 marketing
 direct to consumers. *See* DTC advertising
 direct to physicians. *See* detailing
 disguised 159–160
 drug patent system and 67
 illegal marketing 7–8, 251
 regulation v. innovation 118–121
 spending 191–192
 US drug advertising control 179–181
 Martin, Mark 136
 medical education 14–15, 207–209, 223–227
 medical journals
 bias 111
 fiduciary ideal 241
 ties with industry 11, 15, 111, 152, 156, 251
 Medicare, competitive plans and 44, 49–50
 Melander, Hans 111
 Melarsoprol 4
 Menzel, Paul 6, 62–77
 Merck 5, 8, 10, 11, 108, 139, 140, 151, 152, 159, 191
 Merck Company Foundation 151
 Mercizan 5
 mergers 203
 Millennium Pharmaceuticals 151
 Mills, Ann 13, 198–216
Les Misérables 185–186
 monopolies 43–44, 50

Cambridge University Press

978-0-521-76431-5 - Ethics and the Business of Biomedicine

Edited by Denis G. Arnold

Index

[More information](#)*Index*

289

- monopsonies 43, 44, 45, 50
- Monsanto 152
- moral hazard 46
- Morgagni, Giovanni Battista 243
- Morreim, Haavi 226, 237
- multiculturalism 241
- multinational companies 13, 187

- Nagel, T. 38
- National Institute for Health and Clinical Excellence (NICE) 181
- National Institute of Health (NIH) 119–120, 144
- Nemeroff, Charles 156
- Netherlands 27, 81
- Neurontin 8
- New York University 151
- New Zealand 27, 81, 146, 179
- Newcomer, Lee 108
- Nigeria 6
- North Florida University 151
- Novartis 5, 192

- OECD 2
- off-label use of drugs 7, 251
- Olanzapine 8
- organizational ethics
 - business ethics and 226–227
 - characteristics 212–215, 236–244
 - health of patients and community 240–242
 - healthcare broader than medicine 240
 - holistic health concepts 239–240
 - institutions and individuals 238–239
 - norms and science 242–244
- Orlowski, James 163–164
- orphan drugs 74, 181–182, 183, 194–195
- orthodox bioethics 231–234

- Palmer, Tom 64, 65
- parallel trade 71
- Paris School 224, 243
- patents
 - drugs. *See* drug patents
 - economics 62–63
 - monopolies 179
 - moral arguments for 63–65
- paternalism 228
- Paxil 9
- Pellegrino, Edmund 22, 220–221, 235, 243
- Pennsylvania, University of 7, 151, 152
- Peppin, John 123
- persuasion 88
- Pfizer 6, 8, 9, 133, 135, 136, 137, 139, 151, 152, 158, 159
- pharmaceutical industry. *See* drug industry
- PhRMA 104, 106, 113–115, 131, 133, 136–137, 152, 194

- physicians
 - arrogance and insensitivity 239
 - as agents 235
 - biomedical model 226, 232, 239
 - business rhetoric 199–200, 204–205
 - continuing medical education 117
 - corporatization of medicine 201–202
 - corruption by industry 249–255
 - detailing and. *See* detailing
 - ethics 105
 - fiduciary duties 105, 115, 226, 241
 - knowledge of pharmacology 110
 - patient care ethics 205–215
 - patient–physician relationships 243
 - DTC ads and 134–135, 142, 143
 - physician incentives 29
 - reaction to gifts 117, 163–164, 204
 - sources of information 103–104, 118
 - vulnerability to detailing 109–112
- Plato 21, 22
- pregnant women, vulnerability 86
- Prescription Project 115
- prices. *See* drugs
- prisoners 85, 86, 87–88
- private health insurance 28–29
- privatizations 51, 57
- property, Lockean theory 64
- Propulsid 11
- Provan 6
- Provigil 8
- public goods 67–71
- public health 31, 250
- public relations 158–160
- public trust 161, 253

- Ramsey, Paul 231
- RAND Health Insurance Experiment 46, 47, 52, 56
- Rawls, John 37, 38–39
- Relafen 139
- Relman, Arnold 21
- rescue obligations 184–189
- research
 - biomedical model 223–224
 - IRBs and 232
 - medical practice and 236
 - medical research ethics 205–215
- research and development
 - 10/90 gap 66
 - advanced market commitments 75–76
 - annual expenditure 65
 - British drug pricing system 73
 - clinical trials. *See* clinical trials
 - free-riding 67–71
 - issues 66–67

Cambridge University Press

978-0-521-76431-5 - Ethics and the Business of Biomedicine

Edited by Denis G. Arnold

Index

[More information](#)

290

Index

- research and development (cont.)
 - non-innovative drugs 65, 66–67, 69–71, 119
 - paying for innovation 73–76
 - public goods 67–71
 - R&D-plus 76
 - regulation v. innovation 118–121
 - requirements 62
 - small firms 75
 - Third World diseases 74
- right to health 12–13, 170, 171–177
- right to life 172, 176
- risk, clinical trials 90–93, 94
- Robinson, James 201–202
- Roche 151
- Rorty, Mary 13, 198–216
- Sabin, James 39, 180
- Safer, Daniel 111
- safety of drugs 10–11, 141
- Sanofi-Aventis 151, 158
- Schering-Plough 8, 10, 136
- science
 - bioethics and 234–235, 237
 - Flexner model 199, 200, 223
 - organizational model 242–244
- Sen, Amartya 37
- Senge, Peter 216
- Sepracor 137
- sepsis 160
- Seton Hall University 151
- SFBC International 94
- Singapore 5, 29
- Singer, Peter 185
- sleeping sickness 4
- Smith, Adam 21, 22, 32
- Smith, Richard 251
- SmithKline Beecham 139, 151, 152
- social proof principle 157
- social solidarity 49
- South Africa 29
- stakeholders 208, 209–212
- Stanford University 47, 152
- stem cell research 155
- Stoto, Michael 247
- Sun-Life 151
- supply side constraints 42, 45
- SUPPORT study 222, 233–234
- Sweden 27, 70
- Switzerland 27
- system-based ethics 14, 206–209, 221, 234–236
- Teagarden, Russell 180
- Thailand, generic drug production 5
- Thomasma, David 235, 243
- thought leaders 153, 251
- Toronto University 151, 152
- transnational companies 13, 187
- TRIPS 5, 6, 72, 74, 77
- trust, public trust 161, 253
- tuberculosis 74
- UNICEF 4
- uninsurance 2, 52, 181
- United Health Group 108
- United Kingdom
 - drug prices 70, 73, 190
 - DTP marketing 114
 - expensive drugs and NHS 176
 - healthcare expenditure 2
 - healthcare system 24, 27
 - NICE model 181
- United Nations, draft TNC norms 13
- United States
 - Bay-Dole Act 120
 - care reimbursement 202–203, 205
 - clinical research
 - oversight 83
 - prisoners 87–88
 - rules 90
 - corporatization of medicine 201–202
 - drug budget 65, 70–71
 - drug industry
 - developing countries and 170
 - DTC advertising 9–10, 131–146, 179–181
 - DTP marketing 113–116
 - lobbying 190
 - marketing budget 7
 - non-innovative drugs 66–67
 - orphan drugs 181–182, 183, 194
 - pricing 190–191
 - profitability 3–4, 103, 191–195
 - research 119–120
 - safety 10–11
 - health insurance 2, 52, 181
 - healthcare system
 - budget 1, 2, 103
 - care reimbursement 202–203
 - characteristics 22, 26
 - Clinton plan 25, 36, 44–45, 202, 206
 - corruption 15, 249–255
 - cost crisis 230–231
 - drug pricing control 178–179
 - ethical shift 14, 220, 234–235
 - ethics 205–215
 - international ranking 30
 - market strategies 3, 20, 29, 35–57
 - private healthcare 12
 - shortcomings 177
 - infinite technological innovation 31–33

Index

291

- intellectual property rights 4, 77
- IRBs 153–154
- life expectancy 169
- medical education 14–15, 207–209, 223–227
- Universal Declaration of Human Rights 172
- universal systems 20–21, 39, 40
- University College, London 151
- user fees
 - anti-retroviral therapies 52
 - developing countries 51–52
 - effect 52, 57
- utilitarianism 65
- vaccines 182
- Vanderbilt University 7
- Vasella, Daniel 192
- VERICC 160
- Viagra 9, 136, 137, 140
- Vioxx 10, 11, 12, 108, 139, 159, 191
- Virginia Healthcare Ethics Network 213
- vulnerability
 - concept 86–87
 - economically disadvantaged 84–87
 - physicians to PSRs 109–112
 - vulnerable groups 85, 86
- water 172
- Wateska, Leon 163–164
- Waxman, Henry 9
- Werhane, Patricia 13, 65, 198–216
- Wikler, Daniel 15, 249–257
- Wittgenstein, Ludwig 216
- Woolhandler, S. 43
- World Bank 51
- World Health Organization 5,
11, 13
- WTO. *See* TRIPS
- Wyeth 151
- Xigris 160
- Yale School of Medicine 7
- Zaner, Richard 231
- Ziegler, Michael 106–107
- Zyprexa 8